GCG and metabolic syndrome: Furthermore, SCFAs can stimulate the release of glucagon-like Peptide-1 (GLP-1) from intestinal L-cells, a hormone associated with reduced appetite, increased insulin sensitivity, and improvements in parameters of metabolic syndrome [7].